Teva Pharmaceutical Industries Ltd (TEVA): Teva 2nd-quarter net rose 5.3% on 9.9% h...

Teva Pharmaceutical Industries Ltd (TEVA)

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	29
Posts	5148
Boards Moderated	0
Alias Born	05/24/2006

genisi

Re: None

Wednesday, 08/01/2007 1:41:15 AM

Wednesday, August 01, 2007 1:41:15 AM

Teva 2nd-quarter net rose 5.3% on 9.9% higher sales:

TEVA REPORTS SECOND QUARTER 2007 RESULTS
Jerusalem, Israel, August 1, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today
announced its financial results for the second quarter ended June 30, 2007.
Second Quarter Highlights
· Record-breaking quarterly net sales of $2,386 million, up 10 percent over the second quarter of
2006—a quarter which included the launches with exclusivity of Simvastatin and Pravastatin,
among the largest launches in the industry’s history.
· Net income of $515 million compared to net income of $489 million and adjusted net income of
$541 million in the comparable quarter of 2006.
· Diluted EPS of $0.63 compared to EPS of $0.59 and adjusted diluted EPS of $0.66 in the prior
year quarter.
“This was an excellent quarter for Teva,” said Shlomo Yanai, Teva’s President and CEO. “We are
especially pleased with our record-breaking sales figures, which show an increase of 15 percent over last
quarter, and 10 percent over the second quarter of 2006--a quarter which included two of the largest
launches in our company’s, and the industry's, history. Our results this quarter were driven by strong
performances across all our business units and geographies, by record-breaking sales of Copaxone®,
and by a very successful early launch of Amlodipine/Benazepril.”
snip
I'm not sure the link to RASE works:

http://maya.tase.co.il/bursa/report.asp?report_cd=283479